Abstract
Phenstatin and its derivatives are potential anticancer drug candidates according to their inhibitory properties on tubulin polymerization, cell growth and antivascular activity. However, at the present time, neither pharmacological nor metabolic studies have been conducted in order to strengthen the relevance of phenstatine as a drug discovery candidate. In the present work, the metabolic fate of phenstatin in rat and human microsomal preparations was studied to investigate the stability of this tubulin polymerization inhibitor and any effects of the metabolites on tubulin polymerization and on PC3 cancer cell proliferation. The metabolites were separated by high-performance liquid chromatography and, after their synthesis, characterized by simultaneous LC-DAD-UV and LC-ESI-MS analyses. Thus, eight metabolites were identified. The major biotransformation pathways are carbonyl reduction, O-methylation at C-3, O-methylation after aromatic hydroxylation at the position C-2 on phenyl B ring and O-demethylation on A ring. Four of the identified metabolites were as active or more active, than phenstatin in vitro. Moreover, the better stability of phenstatin versus CA-4 and the lack of quinone formation could justify the design of new analogues which could include various substituents on phenyl rings or linker group in order to modulate the metabolism of phenstatin toward even more active metabolites and so up-regulate the pharmacological activity.
Keywords: Phenstatin, liver microsomes, metabolites, prostate cancer, tubilin polymerization, benzophenone, Combretastatin A-4 (CA-4) analogue, cytotoxicity, antiproliferative activity, electrospray mass spectrometry
Drug Metabolism Letters
Title: In Vitro Metabolism of Phenstatin: Potential Pharmacological Consequences
Volume: 5 Issue: 3
Author(s): Delphine Le Broc-Ryckewaert, Nicole Pommery, Jean Pommery, Alina Ghinet, Amaury Farce, Jean-Francois Wiart, Philippe Gautret, Benoit Rigo and Jean-Pierre Henichart
Affiliation:
Keywords: Phenstatin, liver microsomes, metabolites, prostate cancer, tubilin polymerization, benzophenone, Combretastatin A-4 (CA-4) analogue, cytotoxicity, antiproliferative activity, electrospray mass spectrometry
Abstract: Phenstatin and its derivatives are potential anticancer drug candidates according to their inhibitory properties on tubulin polymerization, cell growth and antivascular activity. However, at the present time, neither pharmacological nor metabolic studies have been conducted in order to strengthen the relevance of phenstatine as a drug discovery candidate. In the present work, the metabolic fate of phenstatin in rat and human microsomal preparations was studied to investigate the stability of this tubulin polymerization inhibitor and any effects of the metabolites on tubulin polymerization and on PC3 cancer cell proliferation. The metabolites were separated by high-performance liquid chromatography and, after their synthesis, characterized by simultaneous LC-DAD-UV and LC-ESI-MS analyses. Thus, eight metabolites were identified. The major biotransformation pathways are carbonyl reduction, O-methylation at C-3, O-methylation after aromatic hydroxylation at the position C-2 on phenyl B ring and O-demethylation on A ring. Four of the identified metabolites were as active or more active, than phenstatin in vitro. Moreover, the better stability of phenstatin versus CA-4 and the lack of quinone formation could justify the design of new analogues which could include various substituents on phenyl rings or linker group in order to modulate the metabolism of phenstatin toward even more active metabolites and so up-regulate the pharmacological activity.
Export Options
About this article
Cite this article as:
Le Broc-Ryckewaert Delphine, Pommery Nicole, Pommery Jean, Ghinet Alina, Farce Amaury, Wiart Jean-Francois, Gautret Philippe, Rigo Benoit and Henichart Jean-Pierre, In Vitro Metabolism of Phenstatin: Potential Pharmacological Consequences, Drug Metabolism Letters 2011; 5 (3) . https://dx.doi.org/10.2174/187231211796904973
DOI https://dx.doi.org/10.2174/187231211796904973 |
Print ISSN 1872-3128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-0758 |
Related Articles
-
Relations between GPR4 Expression, Microvascular Density (MVD) and Clinical Pathological Characteristics of Patients with Epithelial Ovarian Carcinoma (EOC)
Current Pharmaceutical Design Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Progress and Pitfalls in the Identification of Cancer Stem Cell-Targeting Therapies in Head and Neck Squamous Cell Carcinoma
Current Medicinal Chemistry The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Past, Present and Future of Nutrigenomics and its Influence on Drug Development
Current Drug Discovery Technologies Metabolic Alterations in Renal and Prostate Cancer
Current Drug Metabolism Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology Therapeutic Potential of Perineural Invasion, Hypoxia and Desmoplasia in Pancreatic Cancer
Current Pharmaceutical Design Therapeutics Interventions with Anti-Inflammatory Creams in Post Radiation Acute Skin Reactions: A Systematic Review of Most Important Clinical Trials
Recent Patents on Inflammation & Allergy Drug Discovery Assessment of Gene Transfer Using Imaging Methodology
Current Genomics Advancements in Non-steroidal Antiandrogens as Potential Therapeutic Agents for the Treatment of Prostate Cancer
Mini-Reviews in Medicinal Chemistry Serotonergic System and Its Role in Epilepsy and Neuropathic Pain Treatment: A Review Based on Receptor Ligands
Current Pharmaceutical Design NMR-based Metabolite Profiling of Pancreatic Cancer
Current Metabolomics 177Lu-DOTA-Bevacizumab: Radioimmunotherapy Agent for Melanoma
Current Radiopharmaceuticals Role of the Cytoskeleton in Steroidogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Survivin: Role in Normal Cells and in Pathological Conditions
Current Cancer Drug Targets New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry The Chemistry and Pharmacology of Genistein
The Natural Products Journal New Insights Into the Molecular Mechanisms of Action of Bisphosphonates
Current Pharmaceutical Design Processed Foods, Dysbiosis, Systemic Inflammation, and Poor Health
Current Nutrition & Food Science